vaccin
describ
one
success
public
health
intervent
date
modern
vaccinolog
era
start
edward
jenner
english
gener
practition
conduct
first
scientif
investig
smallpox
prevent
sinc
vaccin
reduc
diseas
disabl
death
varieti
infecti
diseas
world
despit
success
still
great
need
new
vaccin
prevent
reduc
impact
outbreak
endem
infecti
diseas
emerg
infecti
diseas
case
eid
especi
challeng
due
fact
ident
pathogen
respons
diseas
well
time
locat
next
outbreak
accur
predict
use
current
mean
histor
vaccin
develop
long
riski
costli
endeavor
plan
vaccin
eid
especi
challeng
potenti
market
vaccin
diseas
limit
test
vaccin
difficult
sever
bottleneck
identifi
develop
vaccin
eid
first
limit
factor
relat
preclin
discoveri
understand
pathogenesi
mechan
develop
appropri
animalchalleng
model
abl
screen
test
gener
proof
concept
poc
new
antigen
deliveri
platform
trivial
moreov
preclin
develop
complex
multistep
timeconsum
process
repres
second
bottleneck
vaccin
develop
process
involv
selectionscreen
appropri
antigen
verif
efficaci
anim
model
follow
process
develop
ensur
scalabl
robust
good
manufactur
practic
gmp
compliant
process
establish
materi
gener
end
preclin
develop
use
anim
toxicolog
studi
form
basi
clinic
trial
applic
tradit
clinic
trial
phase
requir
signific
invest
resourc
execut
lengthi
natur
process
could
describ
bottleneck
mani
eid
prone
sporad
outbreak
morbid
mortal
high
sometim
possibl
conduct
tradit
phase
iii
efficaci
trial
due
ethic
consider
scale
unpredict
natur
eid
outbreak
meet
uniqu
challeng
vaccin
develop
eid
innov
effici
global
system
vaccin
research
develop
r
eid
need
devast
west
african
ebola
epidem
alon
claim
live
peopl
comprehens
econom
social
burden
estim
us
billion
million
per
case
global
need
organ
could
financ
coordin
develop
vaccin
eid
recogn
although
licens
ebola
vaccin
avail
approxim
differ
vaccin
preclin
develop
includ
dna
vaccin
viruslik
particl
vlp
viral
vectorbas
vaccin
took
year
initi
field
trial
first
ebola
vaccin
mani
develop
decad
becam
evid
improv
system
develop
vaccin
known
unknown
epidem
threat
need
earli
idea
establish
becam
coalit
epidem
prepared
innov
cepi
consolid
world
econom
forum
annual
meet
davo
januari
cepi
launch
year
later
facilit
fund
coordin
intern
intergovernment
plan
develop
deploy
new
vaccin
prevent
reduc
impact
eid
epidem
coalit
innov
global
partnership
public
privat
philanthrop
civil
societi
organ
mission
stimul
acceler
develop
vaccin
eid
enabl
access
vaccin
peopl
affect
outbreak
found
govern
norway
india
bill
melinda
gate
foundat
wellcom
trust
world
econom
forum
cepi
secur
approxim
us
million
direct
align
invest
toward
us
billion
fund
target
includ
multiyear
fund
norway
germani
japan
canada
australia
european
commiss
bill
melinda
gate
foundat
wellcom
trust
also
receiv
singleyear
invest
govern
belgium
uk
tabl
mani
organ
oper
within
endtoend
space
vaccin
fund
r
implement
howev
sever
critic
gap
identifi
cepi
design
fill
fig
r
complex
lengthi
expens
potenti
market
vaccin
eid
limit
test
vaccin
difficult
cepi
design
advanc
vaccin
known
threat
poc
safeti
test
human
establish
investig
stockpil
use
emerg
begin
epidem
clinic
trial
regimen
also
fund
new
innov
platform
technolog
carri
potenti
acceler
develop
manufactur
vaccin
previous
unknown
pathogen
moreov
cepi
coordin
activ
improv
collect
respons
epidem
strengthen
capac
countri
risk
advanc
regulatori
scienc
govern
product
develop
cepi
three
strateg
object
prepared
respons
sustain
aim
advanc
safe
effect
vaccin
eid
acceler
research
develop
use
vaccin
outbreak
creat
durabl
equit
solut
outbreak
respons
capac
offer
uniqu
opportun
investor
lead
global
health
secur
partnership
govern
intern
organ
invest
solut
aim
protect
vulner
peopl
world
help
prevent
spread
epidem
world
health
organ
develop
list
diseas
pathogen
priorit
research
develop
r
blueprint
emerg
infect
diseas
priorit
basi
pose
public
health
risk
due
epidem
potenti
insuffici
countermeasur
furthermor
conduct
annual
review
blueprint
prioriti
list
ebola
marburg
lassa
merscov
nipah
rift
valley
fever
rvf
virus
among
virus
list
year
alon
six
prioriti
pathogen
list
r
blueprint
caus
outbreak
diseas
x
also
list
repres
fact
seriou
intern
epidem
could
caus
pathogen
current
unknown
caus
human
diseas
toward
import
enabl
crosscut
r
prepared
cepi
priorit
invest
two
area
first
develop
vaccin
set
highprior
pathogen
current
includ
lassa
merscov
nipah
rvf
chikungunya
virus
second
develop
vaccin
platform
technolog
enabl
rapid
vaccin
develop
manufactur
improv
global
capac
respond
emerg
unknown
pathogen
epidem
potenti
diseas
x
sinc
launch
cepi
announc
three
call
propos
cfp
first
third
cfp
focus
cepi
prioriti
pathogen
support
candid
vaccin
merscov
nipah
lassa
rvf
chikungunya
virus
second
cfp
aim
advanc
rapidrespons
platform
unknown
pathogen
cepi
establish
multipl
partner
agreement
make
current
portfolio
prioriti
pathogen
vaccin
candid
three
rapid
respons
platform
reflect
potenti
invest
us
million
addit
partnership
negoti
tabl
provid
detail
cepi
vaccin
portfolio
detail
also
provid
cepi
websit
wwwcepinet
cepi
vaccin
portfolio
contain
wide
varieti
technolog
rang
across
recombin
viral
vector
nucleic
acidbas
approach
recombin
protein
given
vaccin
develop
larg
empir
scienc
difficult
determin
advanc
technolog
like
succeed
clinic
therefor
cepi
invest
develop
multipl
candid
prioriti
pathogen
prioriti
pathogen
project
cepi
seek
advanc
vaccin
candid
phase
ii
clinic
trial
gener
investig
stockpil
investig
stockpil
could
use
futur
outbreak
clinic
trial
vaccin
technolog
enabl
rapid
respons
cepi
initi
invest
seek
demonstr
preclin
immun
three
pathogen
clinic
phase
respons
two
case
award
made
stringent
mileston
stage
gate
partnership
arrang
establish
also
provid
provis
ensur
cepi
equitableaccess
goal
achiev
current
cepi
invest
five
technolog
lassa
fever
vaccin
use
recombin
virus
nucleic
acidbas
immun
inde
first
cepisponsor
phase
clinic
trial
began
may
use
inovio
pharmaceut
dna
technolog
recent
anoth
phase
clinic
trial
lassa
vaccin
candid
initi
themi
bioscienc
four
vaccin
candid
investig
merscov
similar
combin
technolog
howev
two
recombin
virus
test
alreadi
gain
use
clinic
data
prior
cepi
fund
thu
advanc
state
develop
program
nipah
four
vaccin
develop
includ
recombin
virus
recombin
protein
case
expect
phase
studi
begin
within
month
phase
ii
studi
follow
shortli
afterward
recent
fund
made
avail
partnership
european
commiss
rvf
chikungunya
two
rvf
vaccin
candid
develop
consist
attenu
virus
two
candid
develop
chikungunya
invest
also
made
three
platform
technolog
base
nucleic
acid
recombin
protein
three
potenti
produc
vaccin
rapidli
event
emerg
tabl
addit
invest
area
announc
shortli
develop
biolog
standard
assay
import
evalu
vaccineelicit
immun
respons
promot
standard
transpar
compar
among
vaccin
candid
current
avail
intern
antibodi
standard
lassa
merscov
nipah
wide
varieti
intermedi
standard
current
use
lassa
vaccin
develop
cepi
collabor
intern
partner
collect
serum
patient
endem
countri
recov
actual
diseas
develop
refer
antibodi
prepar
ultim
expert
committe
biolog
standard
ecb
endors
intern
refer
prepar
irp
aim
cepi
make
biolog
standard
avail
cepifund
vaccin
develop
earli
possibl
purpos
cepi
establish
work
group
standard
assay
anim
model
cochair
addit
overarch
group
expert
pathogenspecif
task
forc
also
establish
obtain
advic
specif
topic
relat
standard
assay
anim
model
task
forc
instrument
describ
major
need
diseas
provid
technic
advic
foster
collabor
across
project
diseasespecif
task
forc
engag
scientist
variou
geograph
region
multipl
disciplin
moreov
cepi
also
seek
make
pathogenspecif
antigen
avail
relev
cepifund
vaccin
develop
move
toward
phase
iii
potenti
phase
iii
efficaci
trial
access
common
set
refer
standard
crucial
evalu
vaccin
comparison
differ
vaccin
candid
exampl
past
year
cepi
launch
request
propos
sign
sever
partnership
agreement
distribut
lassa
virusspecif
antigen
develop
lassa
antibodi
standard
collabor
viral
hemorrhag
fever
consortium
vhfc
bernhard
nocht
institut
tropic
medicin
bnitm
nation
institut
biolog
standard
control
nibsc
cepi
collect
serum
individu
recov
diseas
endem
countri
sierra
leon
liberia
mali
nigeria
develop
refer
antibodi
prepar
ultim
irp
avail
global
due
natur
eid
obtain
human
efficaci
data
may
prove
challeng
vaccin
cepi
portfolio
consequ
evid
vaccin
efficaci
may
need
reli
either
part
fulli
data
valid
anim
model
accept
regulatori
author
us
food
drug
administr
fda
final
anim
efficaci
rule
also
known
anim
rule
appli
develop
test
drug
biolog
reduc
prevent
seriou
lifethreaten
condit
caus
exposur
lethal
agent
human
efficaci
trial
feasibl
ethic
accord
rule
fda
reli
anim
studi
provid
substanti
evid
product
effect
akin
tradit
phase
iii
clinic
efficaci
studi
rout
licensur
still
requir
human
safeti
immunogen
howev
reli
anim
efficaci
much
work
need
done
build
foundat
data
natur
histori
studi
one
anim
speci
select
reason
wellunderstood
mechan
toxic
pathogen
pharmacokinet
pharmacodynam
data
suffici
well
understood
allow
select
effect
dose
human
therefor
cepi
plan
support
anim
model
developmentrefin
natur
histori
studi
serv
basi
qualif
model
regulatori
agenc
align
nation
centr
replac
refin
reduct
anim
research
guidelin
acceler
develop
model
tool
avoid
use
anim
possibl
reduc
number
anim
use
per
experi
minim
anim
suffer
improv
welfar
cepi
current
map
exist
effort
fund
work
explor
collabor
cofund
mechan
appropri
avoid
duplic
effort
space
develop
target
product
profil
tpp
mani
prioriti
pathogen
cepi
use
tpp
guid
document
make
mani
decis
regard
feasibl
intend
use
fund
vaccin
diagnost
test
serv
multipl
function
includ
epidemiolog
surveil
diagnosi
efficaci
trial
case
detect
outbreak
respons
cepi
focus
support
develop
diagnost
test
prepar
phase
iibiii
clinic
trial
identifi
case
diseas
effort
map
need
around
develop
diagnost
tool
without
cepi
vaccin
candid
advanc
cepi
limit
fund
diagnosticsrel
activ
therefor
diagnost
work
mainli
accomplish
establish
partnership
collabor
potenti
product
develop
partner
foundat
innov
new
diagnost
find
cepi
develop
partnership
framework
call
cepidx
address
diagnost
need
prioriti
pathogen
cepi
recent
fund
find
total
us
million
support
evalu
serolog
assay
igg
igm
elisa
clinic
trial
site
develop
laboratori
capac
strengthen
lassaaffect
countri
cepi
also
activ
support
find
applic
mobil
total
million
feder
ministri
educ
research
bmbf
german
govern
fund
use
support
clinic
evalu
altona
realstar
lassa
viru
rtpcr
kit
altona
diagnost
hamburg
germani
strengthen
outbreak
surveil
research
capac
activ
relat
biobank
lassaaffect
countri
epidemiolog
studi
essenti
understand
incid
preval
eid
well
clinic
characterist
risk
factor
data
also
essenti
assess
feasibl
clinic
field
efficaci
trial
promis
vaccin
candid
cepifund
vaccin
candid
alreadi
enter
test
phase
clinic
trial
initi
trial
success
vaccin
candid
deem
safe
proceed
next
stage
test
vaccin
phase
iia
trial
affect
countri
potenti
phase
iib
trial
conduct
ensur
feasibl
efficaci
trial
support
trial
design
qualiti
epidemiolog
data
need
epidemiolog
research
also
help
strengthen
site
investig
capac
conduct
clinic
trial
therefor
cepi
provid
grant
epidemiolog
studi
aim
collect
data
contribut
vaccin
develop
support
trial
design
appropri
end
point
site
capac
acceler
lassa
vaccin
develop
cepi
promot
open
call
research
groupsconsortia
across
nigeria
benin
sierra
leon
guinea
liberia
develop
core
studi
protocol
major
multin
epidemiolog
studi
epidemiolog
studi
support
effort
develop
valid
diagnost
assay
collabor
find
moreov
clinic
trial
site
develop
establish
one
fulli
accredit
clinic
trial
site
two
three
site
nigeria
meet
good
clinic
laboratori
practic
gclp
standard
reliabl
diagnosi
lassa
fever
case
carri
support
futur
trial
vaccin
allow
expand
sampl
collect
archiv
acceler
research
develop
regulatori
approv
new
diagnost
vaccin
addit
cepi
provid
support
respect
clinic
develop
vaccin
candid
well
explor
regulatori
pathway
aim
conduct
clinic
trial
affect
endem
countri
earli
develop
possibl
cepi
support
identif
clinic
trial
site
cover
target
popul
engag
capac
build
cooper
brighton
collabor
intern
network
pharmacovigil
expert
among
activ
develop
case
definit
potenti
advers
event
special
interest
aesi
includ
exampl
sensorineur
hear
loss
safeti
evalu
lassa
vaccin
candid
moreov
brighton
collabor
provid
expertis
programspecif
upon
request
crossprogram
pharmacovigil
exampl
establish
metadata
safeti
monitor
board
metadsmb
cepi
prioriti
pathogen
mainli
result
outbreak
essenti
explor
feasibl
field
efficaci
trial
phase
iib
iii
cepi
provid
support
scenario
plan
clinic
trial
design
capac
build
advancedstag
clinic
trial
prove
vaccin
candid
efficaci
infect
diseas
advancedstag
clinic
trial
place
overal
clinic
develop
plan
align
support
relev
regulatori
author
well
prequalif
group
context
cepi
also
explor
altern
regulatori
pathway
case
vaccin
efficaci
demonstr
field
trial
instanc
rapid
declin
infecti
diseas
outbreak
ongo
outbreak
gener
investig
stockpil
candid
vaccin
sustain
suppli
vaccin
critic
cost
time
effici
manufactur
futur
stockpil
outbreak
respons
routin
use
new
vaccin
endem
region
great
import
sinc
mani
vaccin
cepi
develop
find
commerci
market
sustain
cepi
explor
differ
approach
provid
longterm
manufactur
success
vaccin
candid
consid
establish
advanc
manufactur
partnership
limit
number
public
privatesector
manufactur
organ
ongo
effort
understand
potenti
epidem
scenario
model
suppli
chain
stockpil
requir
contribut
effort
vaccin
power
tool
substanti
potenti
prevent
control
outbreak
eid
howev
key
issu
abl
manufactur
test
safe
efficaci
vaccin
immedi
threat
within
short
time
frame
prior
cepi
establish
vaccin
develop
effort
eid
fragment
sustain
mechan
support
success
project
across
vaccin
develop
life
cycl
coordin
work
toward
highestprior
global
epidem
risk
cepi
creat
fill
gap
stimul
financ
coordin
develop
vaccin
eid
especi
case
market
incent
alon
fail
drive
need
develop
creation
cepi
develop
busi
plan
advanc
vaccin
candid
poc
stage
support
phase
ii
clinic
trial
enabl
clinic
efficaci
test
phase
iii
outbreak
also
cepi
intent
contribut
technic
institut
platform
acceler
r
respons
eid
cepi
continu
coordin
close
work
togeth
intern
commun
advanc
vaccin
candid
eid
epidem
potenti
establish
maintain
investig
stockpil
promis
candid
implement
scientif
robust
trial
candid
outbreak
